Michael B. Kastan

Last updated

Michael B. Kastan is the executive director of the Duke Cancer Institute and professor of pharmacology and cancer biology.

Contents

Career

Kastan received his bachelor's degree in chemistry from the University of North Carolina at Chapel Hill and his MD and PhD from Washington University School of Medicine in 1984. [1] He did a residency in pediatrics at Johns Hopkins Hospital. [2]

In 2004, he became director of the Comprehensive Cancer Center at St. Jude Children's Research Hospital, [3] where he worked until moving to Duke to lead the Duke Cancer Institute in 2011. He was the editor-in-chief of Molecular Cancer Research from 2002 to 2012. [4]

Kastan's research is focused on cell signaling and DNA damage and repair mechanisms in cancer. [4]

Awards

Related Research Articles

The Duke University School of Medicine, commonly known as Duke Med, is the medical school of Duke University. It is located in the Collegiate Gothic-style West Campus of Duke University in Durham, North Carolina. The School of Medicine, along with the Duke University School of Nursing, Duke University Hospital, Duke Regional Hospital, Duke Children's Hospital, Duke Raleigh Hospital, and other affiliated hospitals, clinics, and laboratories, make up the Duke University Health System. Established in 1925 by James B. Duke, the School of Medicine has earned its reputation as an integral part of one of the world's foremost patient care and biomedical research institutions.

<span class="mw-page-title-main">Nancy Andrews (biologist)</span> American physician and biologist

Nancy C. Andrews NAS is an American biologist and physician noted for her research on iron homeostasis. Andrews was formerly Dean of the Duke University School of Medicine.

<span class="mw-page-title-main">Cato T. Laurencin</span> American surgeon

Cato T. Laurencin FREng SLMH is an American engineer, physician, scientist, innovator and a University Professor of the University of Connecticut.

Graham Andrew Colditz MD, DrPH is an Australian chronic disease epidemiologist. He is the inaugural Niess-Gain Professor at Washington University School of Medicine, where he is associate director for Prevention and Control at the Alvin J. Siteman Cancer Center. He directs the Master of Population Health Science at Washington University School of Medicine. During medical training he was excited by the potential for prevention of chronic diseases. With encouragement from mentors he pursued training in the US as it was routine for academics in Australia to obtain overseas training at that time. He is internationally recognized for leadership in cancer prevention, and is often interviewed by media for input on this topic. With members of Cancer Prevention and Control at Siteman, he blogs on issues relating to cancer prevention and screening. According to Google Scholar statistics, Colditz has a h-index of more than 300.

<span class="mw-page-title-main">Joseph F. Fraumeni Jr.</span> American physician and cancer researcher

Joseph F. Fraumeni Jr. is an American physician and cancer researcher. Born in Boston, he received an A.B. from Harvard College, an M.D. from Duke University, and an M.Sc. in epidemiology from the Harvard School of Public Health. He completed his medical residency at Johns Hopkins Hospital and Memorial Sloan Kettering Cancer Center. He then joined the National Cancer Institute at the National Institutes of Health in 1962 as a commissioned officer of the U.S. Public Health Service, becoming the founding Director of the Division of Cancer Epidemiology and Genetics in 1995. He stepped down from this position in 2012 to become a senior investigator and advisor to the National Cancer Institute.

<span class="mw-page-title-main">James P. Allison</span> American immunologist and Nobel laureate (born 1948)

James Patrick Allison is an American immunologist and Nobel laureate who holds the position of professor and chair of immunology and executive director of immunotherapy platform at the MD Anderson Cancer Center at the University of Texas.

<span class="mw-page-title-main">Szent-Györgyi Prize for Progress in Cancer Research</span>

The Szent-Györgyi Prize for Progress in Cancer Research, established by National Foundation for Cancer Research (NFCR) and named in honor of Albert Szent-Györgyi, Nobel laureate and co-founder of NFCR, has been awarded annually since 2006 to outstanding researchers whose scientific achievements have expanded the understanding of cancer and whose vision has moved cancer research in new directions. The Szent-Györgyi Prize honors researchers whose discoveries have made possible new approaches to preventing, diagnosing and/or treating cancer. The Prize recipient is honored at a formal dinner and award ceremony and receives a $25,000 cash prize. In addition, the recipient leads the next "Szent-Györgyi Prize Committee" as honorary chairman.

Michael A. Caligiuri is an American physician scientist focused on oncology and immunology. He is currently the president of the City of Hope National Medical Center and the Deana and Steve Campbell Physician-in-Chief Distinguished Chair. He was elected president of the American Association for Cancer Research, the world's largest cancer research organization, for 2017–2018. He was previously the CEO of the James Cancer Hospital (2008-2017), Director of the Comprehensive Cancer Center (2003-2017), and Director of the Division of Hematology-Oncology (2000-2008) at the Ohio State University. He was elected to the United States National Academy of Medicine in 2018.

Charles J. Sherr is the chair of the Tumor Cell Biology Department at St. Jude Children's Research Hospital. He studies tumor suppressor genes and cell division.

Nancy E. Davidson is the executive director and president of Seattle Cancer Care Alliance, senior vice president, director of clinical oncology at Fred Hutchinson Cancer Research Center and head of the Division of Medical Oncology at the University of Washington School of Medicine. She focuses her research on breast cancer treatments and the genes that are mutated in various forms of breast cancer. She was president of American Association for Cancer Research from 2015 to 2016 and president of American Society of Clinical Oncology from 2007 to 2008.

Michael B. Sporn is a professor emeritus of pharmacology, toxicology and medicine at Dartmouth Medical School. His research focuses on the prevention of cancer.

Stephen Bruce Baylin is the deputy director and associate director for research at the Sidney Kimmel Comprehensive Cancer Center and Virginia and D.K. Ludwig Professor for Cancer Research and medicine and chief of cancer biology of the Johns Hopkins University School of Medicine. His research focus is epigenetics in the development of cancer, and he was one of the first researchers in this field in the 1980s.

<span class="mw-page-title-main">Julie Ann Sosa</span> American surgeon

Julie Ann Sosa is a professor and chair of the Department of Surgery at the University of California, San Francisco (UCSF) and holds the Leon Goldman, MD, Distinguished Professorship in Surgery. She currently serves as the Treasurer of the American Thyroid Association and Editor-in-Chief of the World Journal of Surgery.

Charis Eng is a Singapore-born physician-scientist and geneticist at the Cleveland Clinic, notable for identifying the PTEN gene. She is the Chairwoman and founding Director of the Genomic Medicine Institute of the Cleveland Clinic, founding Director and attending clinical cancer geneticist of the institute’s clinical component, the Center for Personalized Genetic Healthcare, and Professor and Vice Chairwoman of the Department of Genetics and Genome Sciences at Case Western Reserve University School of Medicine.

Kornelia Polyak is a professor of medicine at Harvard Medical School and an internationally recognized breast cancer expert.

<span class="mw-page-title-main">Richard Gilbertson</span> British paediatric oncology clinician scientist

Professor Richard James Gilbertson is a paediatric oncology clinician scientist and a Senior Group Leader at the Cancer Research UK Cambridge Institute, University of Cambridge. He is the Li Ka Shing Chair of Oncology, and Director of the CRUK Cambridge Major Centre and the Children's Brain Tumour Centre of Excellence.

<span class="mw-page-title-main">David H. Gutmann</span> American neurologist

David Hillel Gutmann is an American neurologist-neuroscientist. He teaches at Washington University in St. Louis, where he is the Donald O. Schnuck Family Professor, and Director of the Washington University Neurofibromatosis Center. He is an international expert in Neurofibromatosis, pioneering the use of preclinical models to understand brain tumors and neurodevelopmental delays in children with NF1.

Eric Reese Fearon is an American oncologist. He is the Emanuel N. Maisel Professor of Oncology at the University of Michigan and director of the University of Michigan Rogel Cancer Center.

<span class="mw-page-title-main">Chi Van Dang</span> Hematological oncologist

Chi Van Dang is a hematological oncologist and researcher, currently serving as the Scientific Director of Ludwig Institute for Cancer Research. He is known for his research on genetics, the MYC gene and the cellular energy metabolism of cancer.

<span class="mw-page-title-main">Kimryn Rathmell</span> American physician-scientist

W. Kimryn Rathmell is an American physician-scientist whose work focuses on the research and treatment of patients with kidney cancers. She is the Hugh Jackson Morgan Professor and Chair of the Department of Medicine at Vanderbilt University Medical Center (VUMC), and Physician-in-Chief for Vanderbilt University Adult Hospital and Clinics in Nashville, Tennessee. On Nov. 17, 2023, Rathmell was announced as the next Director of the National Cancer Institute.

References

  1. "Michael B. Kastan, MD, PhD".
  2. 1 2 "Duke Cancer Leader Michael Kastan Named to National Academy of Sciences - Duke School of Medicine". medschool.duke.edu.
  3. "Pioneering cancer researcher will lead the new Duke Cancer Institute - DCRI". DCRI. 16 May 2011.
  4. 1 2 3 "Michael B. Kastan, MD, PhD".
  5. "Michael B. Kastan, MD, PhD".